Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN), ACADIA Pharmaceuticals (NASDAQ: ACAD) and Premier (NASDAQ: PINC)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGNResearch Report), ACADIA Pharmaceuticals (ACADResearch Report) and Premier (PINCResearch Report) with bullish sentiments.

Regeneron (REGN)

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Regeneron, with a price target of $630.00. The company’s shares closed last Tuesday at $574.37, close to its 52-week high of $581.00.

According to TipRanks.com, Newman is a 5-star analyst with an average return of 12.6% and a 43.0% success rate. Newman covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Hutchison China MediTech, and Atara Biotherapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Regeneron with a $532.27 average price target, a -5.5% downside from current levels. In a report issued on May 1, Piper Sandler also maintained a Buy rating on the stock with a $550.00 price target.

See today’s analyst top recommended stocks >>

ACADIA Pharmaceuticals (ACAD)

In a report released yesterday, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on ACADIA Pharmaceuticals, with a price target of $56.00. The company’s shares closed last Tuesday at $47.38.

According to TipRanks.com, Kulkarni is a 5-star analyst with an average return of 11.5% and a 46.8% success rate. Kulkarni covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Intra-Cellular Therapies, and Zynerba Pharmaceuticals.

ACADIA Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $59.58.

Premier (PINC)

In a report released yesterday, Richard Close from Canaccord Genuity maintained a Buy rating on Premier, with a price target of $37.00. The company’s shares closed last Tuesday at $30.45.

According to TipRanks.com, Close is a 5-star analyst with an average return of 11.8% and a 58.0% success rate. Close covers the Technology sector, focusing on stocks such as Castlight Health, Health Catalyst, and Livongo Health.

Premier has an analyst consensus of Moderate Buy, with a price target consensus of $35.83.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.